INTERFERONS: ANTIANGIOGENESIS AGENTS (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


INTERFERONS: ANTIANGIOGENESIS AGENTS (MEETING ABSTRACT)

First International Congress on Biological Response Modifiers. March 22-24, 1991, Quebec City, Quebec, Canada, A46, 1991.. Unique Identifier : AIDSLINE ICDB/92679785
Sinkovics JG; Cancer Inst., St. Joseph's Hosp., Tampa, FL

Abstract: In the mouse, murine and human IFN beta inhibited tumor-induced angiogenesis in species-specific fashion and IFNs alpha, beta, and gamma suppressed lymphocyte-induced angiogenesis without inhibiting replication of tumor cells (Sidky and Borden, Cancer Res 47:5155, 1987). In humans, Hu-r-IFN alpha induced remissions of pulmonary hemangiomatosis (White et al, N Engl J Med 320:1197, 1989) and Kaposi's sarcoma (KS; Sinkovics and Szakacs, 14th Int Cancer Congr Budapest 1:223, 1986) without reconstituting immune defects in the latter entity or inducing remission of AIDS in AIDS-KS. We proposed in 1986, that IFNs acted in KS as antiangiogenesis agents. IFN alpha suppresses the bFGF system encoded by the int-hst proto-oncogenes. KS's K-fgf is part of this system. While IFN alpha is active in KS, IFN gamma is inactive. IFN gamma antagonizes aFGF (endothelial cell GF alpha) but not bFGF. Therefore, a member of the bFGF family and not aFGF is one of the active angiogenesis factors operational in KS.
Keywords: Animal Fibroblast Growth Factor, Acidic Fibroblast Growth Factor, Basic/ANTAGONISTS & INHIB Hemangioma/THERAPY Human Interferon Type II/PHARMACOLOGY Interferon-beta/THERAPEUTIC USE Interferons/*THERAPEUTIC USE Lung Neoplasms/THERAPY Lymphocytes Neovascularization, Pathologic/IMMUNOLOGY/*PREVENTION & CONTROL Proto-Oncogenes Sarcoma, Kaposi's/GENETICS/THERAPY Tumor Cells, Cultured ABSTRACT

KWDanimalfibroblastgrowthfactor,acidicfibroblastgrowthfactor,basic/antagonists&inhibhemangioma/therapyhumaninterferontypeii/pharmacologyinterferon-beta/therapeuticuseinterferons/KWDtherapeuticuselungneoplasms/therapylymphocytesneovascularization,pathologic/immunology/KWDprevention&controlproto-oncogenessarcoma,kaposi's/genetics/therapytumorcells,culturedabstract
920530
M9250949

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .